June 14, 2012

Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Neoadjuvant trials introduce new drugs preoperatively in patients with localized breast cancer, using the rate of pathological complete response as the primary end point. The FDA has issued guidance for using this end point in applying for accelerated drug approval.

Me gusta

Guardar

Cite This Study

Prowell et al. (Thu,) studied this question.

synapsesocial.com/papers/6a0cdc8cd2f99fbc58fc065d https://doi.org/https://doi.org/10.1056/nejmp1205737

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer2008 · 2,907 citations
2Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer2005 · 5,353 citations
3Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes2012 · 2,675 citations
4Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort2010 · 1,268 citations
5Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-312005 · 807 citations

Me gusta

Guardar